The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press release from ...

Veligrotug, an IGF-1R inhibitor, is under FDA Priority Review for thyroid eye disease based on positive phase 3 trial data.

Abbvie ($ABBV) announced an update on their ongoing clinical study. Study OverviewAbbVie is running a phase 3 trial called “A ...

(Reuters) -Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the ...

A panelist discusses how dry eye disease involves tear film imbalance, leading to inflammation and ocular surface damage, emphasizing the importance of precise diagnosis and tailored treatment while ...

Eye care practitioners have a wealth of new information to inform their handling of dry eye disease with the third iteration ...

Thyroid eye disease is a chronic autoimmune disorder causing inflammation in the muscles and other tissues behind the eye. It can lead to other eye complications, including glaucoma. Thyroid eye ...

Dry eye disease (DED) is a prevalent, chronic condition diagnosed in about 16.4 million Americans, with an additional 6 million undiagnosed patients experiencing dry eye symptoms. 1 The prevalence of ...

Biopharmaceutical company Dompé has enrolled the first patients in its phase 3 study of isocyclosporin for the treatment of ...

A clinical trial is investigating whether a stem cell-derived patch can replace disease-damaged cells and restore vision. Age-related macular degeneration is a steadily worsening eye disease and the ...

Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with ...

Dry eye syndrome occurs when tear regulation becomes disrupted, either through decreased production or excessive evaporation. This common ocular condition affects millions of people worldwide, ...